Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Gd³⁺ cFLFLFK conjugate for MRI: a targeted contrast agent for Formyl Peptide Receptor 1 in inflammationGraeme J. Stasiuk,^{a,b} Helen Smith,^b Marzena Wylezinska-Arridge,^c Jordi L. Tremoleda,^c William Trigg,^d Sajinder Kaur Luthra,^d Veronique Morisson Iveson,^d Felicity N. E. Gavins^{b*} and Nicholas J. Long^{a*}⁵ Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

Formyl Peptide Receptors (FPRs) are vital in the host inflammatory response, playing an important regulatory role in multiple diseases. A Gd(III) DOTA conjugate of cFLFLFK has been synthesised which targets and visualises FPR1 upon leukocytes in the inflammatory response via magnetic resonance imaging for the first time.

Magnetic resonance imaging (MRI) is a powerful non-invasive diagnostic tool used in clinical medicine. It provides highly detailed three-dimensional images of organs, tissues and blood-flow within the human body, through visualizing water protons within the subject. As a result of the high abundance of water molecules in biological systems, it is able to detect a wide variety of pathological conditions, such as heart disease¹, cancer² and musculoskeletal disorders.³ Paramagnetic metals such as gadolinium within a stable chelate have been used very successfully as contrast agents in MRI, enhancing signal intensity to aid in the diagnosis of numerous disease states over the last 25 years.⁴

The host inflammatory response is a complex process characterised by multiple molecular and cellular phenomena, including the rolling, adherence and emigration of leukocytes from vasculature into parenchymal tissue at sites of inflammation.⁵ These phenomena contribute to widely recognised clinical manifestations of inflammation i.e. pain, fever, redness, swelling and in the case of chronic inflammation (such as rheumatoid arthritis) loss of function.⁶ Although inflammation is critical for pathogen-removal, effective resolution and tissue recovery is dependent on a fine balance between pro- and anti-inflammatory mediators, with stringent temporal and quantitative restrictions on each.⁶ Neutrophils are the most abundant leukocyte in humans and typically the first type of white cell recruited to sites of inflammation.^{6,7} The ability to detect and quantify neutrophilic infiltration into the tissue with a non-invasive technique, such as MRI, will enable the identification of inflammatory lesions and provide a useful screening tool for multiple disease states.

The FPRs are a family of seven transmembrane domain G-protein-coupled receptors (GPCRs), found on leukocytes.⁸ FPR1 is a highly abundant cell surface receptor on neutrophils, expressed under inflammatory conditions, which mediates emigration to the site of injury. Several agonists and antagonists bind to members of the FPRs with various potencies and specificities; in particular, the peptide antagonist cFLFLFK, which specifically binds FPR1.⁹

cFLFLFK is a hexapeptide with a cinnamoyl group at the c-terminus, which has previously been modified with a PEG-DOTA motif by Locke *et al.* for use as a positron emission tomography (PET) imaging agent with ⁶⁴Cu, a PEG-TKPPR-^{99m}Tc for Single Photon Emission Computed Tomography (SPECT) and with a cyanine-7 for optical imaging.¹⁰

⁶⁰ Scheme 1. Synthesis of Gd.1

In this paper we show the design, synthesis and validation of the first MRI contrast agent that specifically targets FPR1 receptors in inflamed tissues.

The desired Gd(III) contrast agent was synthesised from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and cFLFLFK as shown in Scheme 1, with an overall yield of 65%. Conjugation of the DOTA motif was achieved using EDC and NHS at stoichiometric ratio to allow for only one carboxyl group on the DOTA to react with the amine on the n-terminal lysine residue, forming an amide bond and providing the proligand (4) which was purified *via* HPLC. GdCl₃·6H₂O was reacted with the proligand (4) in H₂O at pH 5.5 to give Gd.1 in 88% yield. Relaxivity is a measure of how effective the contrast

agent would be in an MRI experiment. The $r_1 = 5.4 \text{ mM}^{-1}\text{s}^{-1}$ (400 MHz, 9.4 T) value is within the range for a Gd chelate with a hydration state of 1, which is expected for the eight coordinate macrocycle. **Gd.DOTA** the gold standard commercial contrast agent, has an $r_1 = 4.2 \text{ mM}^{-1}\text{s}^{-1}$.¹¹ The slight increase in relaxivity of **Gd.1** can be attributed to its larger mass and even at fields such as 9.4T it presents a high relaxivity for a single chelate agent.¹²

In order to validate the specificity of **Gd.1** for FPR1, receptor-binding assays were undertaken. The receptor binding constant was obtained using Human Embryonic Kidney (HEK) cells stably expressing FPR1. The assay was a competition study with ¹²⁵I-labelled fMLP-analogue and **Gd.1**. The $K_d = 4.5 \text{ nM}$, which is a slight change from the native peptide with a $K_d = 2 \text{ nM}$,¹³ thus illustrating that the **Gd.1** still binds FPR1 in a similar manner as the native peptide. Therefore the choice of conjugation upon the lysine residue does not disrupt the binding to FPR1. This confirmation of high relaxivity for a single molecule contrast agent and the specific binding to FPR1 provides a very useful targeted contrast agent for disease states indicated by inflammation.

In order to investigate the imaging capabilities of **Gd.1** with regards to FPR1, *in-vivo* experiments were set up. C57BL/6 mice were treated for 24 hours with lipopolysaccharide (LPS. 10 $\mu\text{g}/\text{mouse}$ intraperitoneally (i.p.)). LPS is a bacterial fragment that disrupts the vascular endothelium, causing sites of inflammation and the recruitment of activated neutrophils, following which, 1 mmol/kg of **Gd.1/Gd.DOTA** was injected intravenously. These proof of principle *in-vivo* experiments demonstrate the binding of **Gd.1** to FPR1. This is seen in Figure 1A-B: pre-injection on the left (1A), shows the base line and instantly after injection there is a significant increase in signal intensity around the right ear at eight minutes (1B). The signal intensity increases over a twenty minute period as the agent passes around the circulation system, allowing for binding to the FPR1 receptors on blood-borne neutrophils. The signal intensity then levels off and is retained for up to eighty minutes. This demonstrates that **Gd.1** binds to FPR1 on neutrophils/leukocytes, which have localised around sites of inflammation, in this case behind the right ear.

Beyond 80 minutes the agent is localised in high concentrations (*i.e.* large numbers of neutrophils have collected at the site of inflammation) which triggers a T_2 effect, or darkening (Supplementary S1), for up to four hours. This is compared to **Gd.DOTA** (Figure 1 C-E)) which is a commercially available blood pool agent, showing signal increase at the site of injection, but which after 80 minutes shows no detectable increase in intensity. This illustrates the efficiency of **Gd.1** in binding FPR1 on the surface of neutrophils. From the study it is clear that **Gd.1** can be used to observe the movement of leukocytes to the sites of injury

Conclusions

In conclusion, we have shown that cFLFLFK can be conjugated with DOTA and coordinated to lanthanide metals, forming a mono-aqua coordinated complex. Gd(III) has been used to create the first targeted MRI contrast agent that binds to neutrophils expressing FPR1. It has subsequently been shown to image neutrophils during an inflammatory response for up to four hours, with excellent contrast at high fields (9.4 T). This has far

reaching implications for the identification of disease states involved in the inflammatory process and could also ultimately be used as a screening tool in drug discovery.

Figure 1. MRI images of a mouse brain. A) before injection and B) 80 minutes after injection with **Gd.1**. C) pre-injection D) 1 minute and E) 80 minutes after injection with **Gd.DOTA**. 1 mmol/Kg (**Gd.agent**) 37°C, Arrows indicate site of increased signal intensity due to **Gd.agent**.

Acknowledgements

We would like to thank Drs. Ji-Liang Gao, Philip Murphy and Professor Mauro Perretti for the HEK-FPR1 cells, and Professor Sir Steve Bloom, Professor Mohammad Gbatei, Andrew Hogben and Dr James Minnion for help with the receptor binding assays. The BBSRC and GE Healthcare are thanked for funding and an Industry Interchange award.

Notes and references

^a Department of Chemistry, Imperial College London, South Kensington Campus, London SW7 2AZ, UK. Tel: +44 (0)20 7594 5781; Fax: +44 (0)207 5945804; E-mail: n.long@imperial.ac.uk

^b Division of Brain sciences, Department of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, UK. Tel: +44 (0)20 7594 6586; Fax: +44 (0)20 7594 6548; E-mail: f.gavins@imperial.ac.uk

^c Biological Imaging Centre, Imperial College London, Du Cane Road, London, W12 0NN

^d GE Healthcare, The Grove Centre, White Lion Road, Amersham, Buckinghamshire, HP7 9LL UK

† Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/b000000x/

1. K. M. Donahue, D. Burstein, W. J. Manning and M. L. Gray, *Magn. Res. Med.* 1994, **32**, 66-76.

2. P. A. Sukerker, K. W. MacRenaris, T. R. Townsend, R. A. Ahmed, J. E. Burdette and T. J. Meade, *Bioconj. Chem.* 2011, **22**, 2304-2316.

3. S. Blemker, D. Asakawa, G. Gold and S. Delp, *J. Magn. Res. Imaging*, 2007, **25**, 441-451.

-
4. P. Caravan, *Chem. Soc. Rev.*, 2006, 512-523; R. E. Mewis and S. J. Archibald, *Coord. Chem. Rev.*, 2010, **254**, 1686-1712.
5. K. Ley, C. Laudanna, M. Cybulsky and S. Nourshargh, *Nature Rev. Immunology*, 2007, **7**, 678-689.
- 5 6. C. Nathan, *Nature*, 2002, **420**, 846-852; Y. Le, Y. Yang, Y. Cui, H. Yazawa, W. Gong, C. Qui and J. M. Wang, *Int Immunopharmacol* 2002, **2**, 1-13.
7. A.D. Kennedy and F.R. DeLeon, *Immunol. Res*, 2009, **43**, 25-61. .
8. R. D. Ye, F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan and P. M. Murphy, *Pharmacol. Rev.*, 2009, **61**, 119-161.
- 10 9. F. N. E. Gavins, *Trends in pharmacol. Sci.*, 2010, **31**, 266-276.
10. L. W. Locke, M. D. Chordia, Y. Zhang, B. Kundu, D. Kennedy, J. Landseadel, L. Xiao, K. D. Fairchild, S. S. Berr, J. Linden and D. Pan, *J. Nucl. Med.*, 2009, 790-797; Y. Zhang, L. Xiao, M. D. Chordia, L. W. Locke, M. B. Williams, S. S. Berr and D. Pan, *Bioconjug. Chem.*, 2010, **27**, 1788-1793; L. Xiao, Y. Zhang, Z. Liu, M. Yang, L. Pu and D. Pan, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 3515-3517.
- 15 11. P. Caravan, J. J. Ellison, T. J. McMurphy and R. B. Lauffer, *Chem. Rev.*, 1999, **99**, 2293-2352.
- 20 12. A. E. Merbach and E. Toth *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*; Wiley, 2001.
13. C. J. Palestro, *J. Nucl. Med.*, 2009, **50**, 671-673.